Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Altimmune Inc.

The latest announcement is out from Altamira Gold Corp ( ($TSE:ALTA) ). Altamira Gold Corp. has strengthened its board of directors with the appoin...

Altamira Gold Adds Renowned Macro Investor Tavi Costa to Board

Insiders have been trading these 5 stocks: (($GTLB)), (($ALT)), (($LNG)), (($PACB)) and (($HTGC)). Here is a breakdown of their recent trades and t...

Gitlab, Altimmune, Cheniere, Pacific Biosciences, Hercules Shock Wall Street

An announcement from Alta Equipment Group ( ($ALTG) ) is now available. On April 3, 2026, Alta Equipment Group Inc. announced that its board of dir...

Alta Equipment Group Declares Quarterly Preferred Stock Dividend

Alvarium Tiedemann Holdings, Inc. (($ALTI)) has held its Q4 earnings call. Read on for the main highlights of the call. Alvarium Tiedemann Holdings...

Alvarium Tiedemann Earnings Call: Growth Amid Heavy Noise

An announcement from Aeonian Resources Corp ( ($TSE:ALTN) ) is now available. Aeonian Resources has started its first diamond drill program of 2026...

Aeonian Launches First Drill Program at Jake Zone on Koocanusa Copper-Silver Project

Total Helium Ltd ( ($TSE:ALTU) ) has issued an announcement. Altura Energy Corp. has begun a pipeline replacement and infrastructure upgrade progra...

Altura Energy Starts Pipeline Upgrades to Bolster Helium Output at Arizona Field

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Gal...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Galectin Therapeutics (GALT)

Altitude ( ($GB:ALT) ) has provided an update. Altitude Group reported a strong trading performance for the year to 31 March 2026, with revenue exp...

Altitude Group lifts revenue above expectations amid strategic refocus and cost restructuring

H.C. Wainwright analyst Amit Dayal maintained a Buy rating on Alto Ingredients on March 27 and set a price target of $7.00. The company’s shares cl...

H.C. Wainwright Sticks to Its Buy Rating for Alto Ingredients (ALTO)

ALT5 Sigma Corporation ( ($ALTS) ) has released a notification of late filing. ALT5 Sigma Corporation has notified the SEC that it will be late in ...

ALT5 Sigma Delays Annual Report Amid Big Loss

Morella Corporation ( ($AU:1MC) ) has shared an announcement. Morella Corporation Limited has notified the ASX of a proposed placement involving th...

Morella Corporation plans May share placement to expand capital base

The latest update is out from Morella Corporation ( ($AU:1MC) ). Morella Corporation Limited has lodged a notice with the ASX outlining a proposed ...

Morella Corporation Plans New Share Placement to Raise Capital

The latest update is out from Morella Corporation ( ($AU:1MC) ). Morella Corporation Limited has notified the ASX of its intention to issue up to 8...

Morella Corporation Plans Placement of Up to 8 Million New Shares

Morella Corporation ( ($AU:1MC) ) has issued an announcement. Morella Corporation Limited has called an Extraordinary General Meeting for 29 April ...

Morella calls April 2026 EGM to ratify major share placement and options issue

Northland Securities analyst Ted Jackson maintained a Buy rating on Alta Equipment Group today and set a price target of $17.00. According to TipRa...

Alta Equipment Group (ALTG) Receives a Buy from Northland Securities

Galectin Therapeutics ( ($GALT) ) has provided an announcement. On March 12, 2026, Galectin Therapeutics appointed internationally recognized neuro...

Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board

Alto Ingredients, Inc. (ALTO) has disclosed a new risk, in the Taxation & Government Incentives category. Alto Ingredients, Inc. faces execution an...

Alto Ingredients’ Low-Carbon Fuel Strategy Exposed to Section 45Z Tax Credit Risks and 2025–2029 Sunset

Insiders have been trading these 5 stocks: (($ALT)), (($COHR)), (($GSAT)), (($BBBY)) and (($LIN)). Here is a breakdown of their recent trades and t...

Altimmune, Coherent, Globalstar, Bed Bath & Beyond, Linde Insider Shocks

The latest update is out from Altitude ( ($GB:ALT) ). Altitude Group has granted 1,000,000 share options to independent non-executive director Bob ...

Altitude Grants 1 Million Share Options to Non-Executive Director Bob Wigley

Alta Equipment Group, Inc. (($ALTG)) has held its Q4 earnings call. Read on for the main highlights of the call. Alta Equipment Group’s latest earn...

Alta Equipment Group Charts Cautious Recovery Path

Altimmune (($ALT)) has held its Q4 earnings call. Read on for the main highlights of the call. Altimmune’s latest earnings call struck an upbeat to...

Market Cap	$400.72M	P/E Ratio	N/A
52W High	$7.73	52W Low	$2.87
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	17.1%	52W Position	10.5%
Overall Score	30	Value Score	60
Quality Score	23	Technical Score	9

EPS Current Est	$-1	EPS Next Est	$-1
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALT	$3.38	0.00%	2.03M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALT	$3.38	0%	2.03M
3
4
5
6

ALT

ALT

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Altimmune Inc. Data in Excel

Get Altimmune Inc. Data in Excel